Table 5.
Experimental T-MHC restriction epitopes from Plasmodium falciparum that share homology with predicted SARS-CoV-2 ORF T-cell MHC epitopes
| P. falciparum |
SARS-CoV-2 |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | Sequence | Mapped start–end | Epitope antigen name | Epitope parent name | MHC allele | Sequence | Protein name | Mapped start–end | Identity (%) |
| 9041 | DLDEPEQFRL | 543–552 | TRAP precursor | TRAP | HLA-A∗02:01 | IVDEPEEHV | ORF3a | 236–244 | 44.4 |
| 20762 | GLALLACAGL | 504–513 | TRAP precursor | TRAP | HLA-A∗02:01 | ALLAVFQSA | ORF3a | 51–59 | 44.4 |
| 68914 | VICSFLVFL | 9–17 | Hypothetical protein PFL0800c | Uncharacterized protein | HLA-A∗02:03, HLA-A∗02:06 | LVFLGIITTV | ORF8 | 4–13 | 44.4 |
| 68915 | VICSFLVFLV | 9–18 | HLA-A∗02:03, HLA-A∗02:06 | 40 | |||||
| 16939 | FLVFLVFSNV | 13–22 | HLA-A∗02:06 | 40 | |||||
| 16939 | FLVFLVFSNV | 13–22 | Hypothetical protein PFL0800c | Uncharacterized protein | HLA-A∗02:01, HLA-A∗02:03 | FLVFLGIITT | ORF8 | 3–12 | 50 |
| 68914 | VICSFLVFL | 9–17 | HLA-A∗02:01, HLA-A∗02:03 | 55.6 | |||||
| 68915 | VICSFLVFLV | 9–18 | HLA-A∗02:01, HLA-A∗02:03 | 50 | |||||
| 16939 | FLVFLVFSNV | 13–22 | Hypothetical protein PFL0800c | Uncharacterized protein | HLA-A∗02:06 | LVFLGIITT | ORF8 | 4–12 | 44.4 |
| 68914 | VICSFLVFL | 9–17 | HLA-A∗02:06 | ||||||
| 68915 | VICSFLVFLV | 9–18 | HLA-A∗02:06 | ||||||
HLA, human leukocyte antigen; MHC, major histocompatibility complex; ORF, open reading frame; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TRAP, thrombospondin-related anonymous protein.